Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$577.95
2.260.39%
À la fermeture: -
$578.00
0.050.01%
Après les heures de négociation: Oct 24, 5:49 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Regeneron Pharmaceuticals Inc a un objectif de cours consensus de $835.42, basé sur les évaluations des 26 analystes. Le plus élevé est de $1200 attribué par TD Cowen le juillet 23, 2024, et le plus bas est de $547 attribué par B of A Securities le avril 17, 2025. Les 3 dernières évaluations d'analystes ont été publiées par Canaccord Genuity, Canaccord Genuity et Citigroup le octobre 23, 2025, octobre 14, 2025 et octobre 13, 2025. Avec un objectif de cours moyen de $786.67 entre Canaccord Genuity, Canaccord Genuity et Citigroup, il y a une variation implicite de 36.10% upside pour Regeneron Pharmaceuticals Inc à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Canaccord Genuity
Citigroup
Morgan Stanley
Bernstein
Jefferies
1calculé à partir des notes des analystes
Notes d'analystes pour Regeneron Pharmaceuticals
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/23/2025 | 47.06% | Canaccord Genuity | $850 → $850 | Maintains | Buy | |||
10/14/2025 | 47.06% | Canaccord Genuity | $850 → $850 | Maintains | Buy | |||
10/13/2025 | 14.19% | Citigroup | $650 → $660 | Maintains | Buy | |||
10/10/2025 | 30.8% | Morgan Stanley | $761 → $756 | Maintains | Overweight | |||
08/27/2025 | 35.12% | Bernstein | $753 → $781 | Maintains | Outperform | |||
08/27/2025 | 43.77% | Jefferies | $813 → $831 | Maintains | Buy | |||
08/11/2025 | 40.48% | Truist Securities | $940 → $812 | Maintains | Buy | |||
08/04/2025 | 10.73% | BMO Capital | $600 → $640 | Maintains | Outperform | |||
08/04/2025 | 31.66% | Morgan Stanley | $754 → $761 | Maintains | Overweight | |||
08/04/2025 | 20.24% | RBC Capital | $688 → $695 | Maintains | Sector Perform | |||
08/04/2025 | 41% | Guggenheim | $810 → $815 | Maintains | Buy | |||
07/23/2025 | 47.06% | Canaccord Genuity | $850 → $850 | Maintains | Buy | |||
07/11/2025 | 1.04% | UBS | $560 → $584 | Maintains | Neutral | |||
07/10/2025 | 30.45% | Morgan Stanley | $755 → $754 | Maintains | Overweight | |||
06/09/2025 | 38.41% | JP Morgan | $950 → $800 | Maintains | Overweight | |||
06/05/2025 | -3.11% | UBS | $633 → $560 | Maintains | Neutral | |||
06/02/2025 | 12.46% | Citigroup | $700 → $650 | Maintains | Buy | |||
06/02/2025 | 3.81% | BMO Capital | $800 → $600 | Maintains | Outperform | |||
06/02/2025 | 30.62% | Morgan Stanley | $958 → $755 | Maintains | Overweight | |||
05/30/2025 | 0.35% | Wells Fargo | $700 → $580 | Downgrade | Overweight → Equal-Weight | |||
05/27/2025 | 63.15% | RBC Capital | $943 → $943 | Reiterates | Outperform → Outperform | |||
05/14/2025 | 21.11% | Citigroup | $600 → $700 | Upgrade | Neutral → Buy | |||
05/05/2025 | 65.74% | Morgan Stanley | $1081 → $958 | Maintains | Overweight | |||
05/01/2025 | 40.14% | Guggenheim | $940 → $810 | Maintains | Buy | |||
04/30/2025 | 64.36% | JP Morgan | $1000 → $950 | Maintains | Overweight | |||
04/30/2025 | 62.63% | Truist Securities | $975 → $940 | Maintains | Buy | |||
04/30/2025 | 39.1% | Goldman Sachs | $917 → $804 | Maintains | Buy | |||
04/30/2025 | 63.15% | RBC Capital | $1051 → $943 | Maintains | Outperform | |||
04/30/2025 | 21.11% | Wells Fargo | $750 → $700 | Maintains | Overweight | |||
04/30/2025 | 38.41% | BMO Capital | $865 → $800 | Maintains | Outperform | |||
04/30/2025 | 9.52% | UBS | $768 → $633 | Maintains | Neutral | |||
04/30/2025 | 1.56% | Baird | $652 → $587 | Maintains | Neutral | |||
04/29/2025 | 55.71% | Oppenheimer | $925 → $900 | Maintains | Outperform | |||
04/25/2025 | 12.8% | Baird | $759 → $652 | Maintains | Neutral | |||
04/23/2025 | 68.69% | Truist Securities | $1004 → $975 | Maintains | Buy | |||
04/22/2025 | 47.06% | Canaccord Genuity | $1152 → $850 | Maintains | Buy | |||
04/22/2025 | 20.24% | Cantor Fitzgerald | → $695 | Assumes | → Overweight | |||
04/17/2025 | -5.36% | B of A Securities | $575 → $547 | Maintains | Underperform | |||
04/14/2025 | 58.65% | Goldman Sachs | $1019 → $917 | Maintains | Buy | |||
04/09/2025 | 87.02% | Morgan Stanley | $1150 → $1081 | Maintains | Overweight | |||
04/03/2025 | 60.03% | Oppenheimer | $950 → $925 | Maintains | Outperform | |||
03/31/2025 | 73.01% | JP Morgan | $1100 → $1000 | Maintains | Overweight | |||
02/05/2025 | 31.31% | Baird | $940 → $759 | Maintains | Neutral | |||
02/05/2025 | 44.29% | Leerink Partners | $762 → $834 | Upgrade | Market Perform → Outperform | |||
01/28/2025 | 31.83% | Leerink Partners | $880 → $762 | Maintains | Market Perform | |||
01/28/2025 | 29.76% | Citigroup | $795 → $750 | Maintains | Neutral | |||
01/27/2025 | 75.26% | Piper Sandler | $1195 → $1013 | Maintains | Overweight | |||
01/16/2025 | 27.68% | UBS | $1130 → $738 | Downgrade | Buy → Neutral | |||
01/14/2025 | 37.54% | Citigroup | $895 → $795 | Maintains | Neutral | |||
01/10/2025 | 64.36% | Oppenheimer | $1000 → $950 | Maintains | Outperform | |||
01/10/2025 | 55.71% | Wells Fargo | $1050 → $900 | Maintains | Overweight | |||
01/08/2025 | 73.7% | Truist Securities | $1126 → $1004 | Maintains | Buy | |||
01/07/2025 | 85.12% | Bernstein | $1110 → $1070 | Maintains | Outperform | |||
12/10/2024 | -2.25% | B of A Securities | → $565 | Reinstates | → Underperform | |||
11/15/2024 | 98.96% | Wolfe Research | → $1150 | Initiates | → Outperform | |||
11/14/2024 | 54.84% | Citigroup | → $895 | Initiates | → Neutral | |||
11/06/2024 | 73.01% | Oppenheimer | $1150 → $1000 | Maintains | Outperform | |||
11/01/2024 | 52.25% | Leerink Partners | $1077 → $880 | Maintains | Market Perform | |||
11/01/2024 | 104.84% | Morgan Stanley | $1235 → $1184 | Maintains | Overweight | |||
11/01/2024 | 110.21% | RBC Capital | $1260 → $1215 | Maintains | Outperform | |||
11/01/2024 | 84.26% | Barclays | $1080 → $1065 | Maintains | Overweight | |||
11/01/2024 | 106.75% | Piper Sandler | $1242 → $1195 | Maintains | Overweight | |||
11/01/2024 | 105.88% | BMO Capital | $1300 → $1190 | Maintains | Outperform | |||
11/01/2024 | 94.81% | Truist Securities | $1137 → $1126 | Maintains | Buy | |||
10/25/2024 | 117.99% | RBC Capital | $1260 → $1260 | Reiterates | Outperform → Outperform | |||
10/24/2024 | 103.29% | Evercore ISI Group | $1250 → $1175 | Maintains | Outperform | |||
10/24/2024 | 98.96% | JP Morgan | $1200 → $1150 | Maintains | Overweight | |||
10/23/2024 | 75.61% | Cantor Fitzgerald | $1015 → $1015 | Reiterates | Neutral → Neutral | |||
10/23/2024 | 86.85% | Barclays | $1220 → $1080 | Maintains | Overweight | |||
10/22/2024 | 81.66% | Wells Fargo | $1200 → $1050 | Maintains | Overweight | |||
10/22/2024 | 117.99% | RBC Capital | $1260 → $1260 | Reiterates | Outperform → Outperform | |||
10/16/2024 | 96.71% | Truist Securities | $1200 → $1137 | Maintains | Buy | |||
10/04/2024 | 117.99% | RBC Capital | $1252 → $1260 | Maintains | Outperform | |||
09/24/2024 | 116.61% | RBC Capital | $1282 → $1252 | Maintains | Outperform | |||
09/24/2024 | 124.91% | BMO Capital | $1300 → $1300 | Reiterates | Outperform → Outperform | |||
09/24/2024 | 107.61% | Truist Securities | $1200 → $1200 | Reiterates | Buy → Buy | |||
09/24/2024 | 86.33% | Leerink Partners | $1175 → $1077 | Downgrade | Outperform → Market Perform | |||
09/23/2024 | 107.61% | Wells Fargo | $1200 → $1200 | Reiterates | Overweight → Overweight | |||
09/17/2024 | 121.8% | RBC Capital | $1282 → $1282 | Reiterates | Outperform → Outperform | |||
09/16/2024 | 75.61% | Cantor Fitzgerald | $1015 → $1015 | Reiterates | Neutral → Neutral | |||
09/09/2024 | 75.61% | Cantor Fitzgerald | $1015 → $1015 | Reiterates | Neutral → Neutral | |||
09/09/2024 | 121.8% | RBC Capital | $1250 → $1282 | Maintains | Outperform | |||
09/05/2024 | 116.26% | RBC Capital | $1250 → $1250 | Reiterates | Outperform → Outperform | |||
08/23/2024 | 114.88% | Piper Sandler | $1166 → $1242 | Maintains | Overweight | |||
08/02/2024 | 107.61% | JP Morgan | $1150 → $1200 | Maintains | Overweight | |||
08/02/2024 | 114.53% | RBC Capital | $1232 → $1240 | Maintains | Outperform | |||
08/02/2024 | 124.91% | Guggenheim | $1180 → $1300 | Maintains | Buy | |||
08/02/2024 | 107.61% | Wells Fargo | $1125 → $1200 | Maintains | Overweight | |||
08/02/2024 | 111.07% | Barclays | $1200 → $1220 | Maintains | Overweight | |||
08/02/2024 | 107.61% | Truist Securities | $1135 → $1200 | Reiterates | Buy → Buy | |||
07/23/2024 | 107.61% | TD Cowen | $1030 → $1200 | Maintains | Buy | |||
07/22/2024 | 73.01% | Cantor Fitzgerald | $925 → $1000 | Maintains | Neutral | |||
07/19/2024 | 101.73% | Piper Sandler | $1000 → $1166 | Maintains | Overweight | |||
07/18/2024 | 104.15% | Guggenheim | $1040 → $1180 | Maintains | Buy | |||
07/11/2024 | 104.5% | Morgan Stanley | $1183 → $1182 | Maintains | Overweight | |||
07/10/2024 | 107.61% | Barclays | $1050 → $1200 | Maintains | Overweight | |||
06/27/2024 | 99.31% | Canaccord Genuity | $1152 → $1152 | Maintains | Buy | |||
06/25/2024 | 102.42% | Argus Research | $1060 → $1170 | Maintains | Buy | |||
06/24/2024 | 112.63% | RBC Capital | $1229 → $1229 | Reiterates | Outperform → Outperform | |||
06/17/2024 | 98.96% | JP Morgan | $1050 → $1150 | Maintains | Overweight |
FAQ
Quel est le cours indicatif de l'action Regeneron Pharmaceuticals (REGN) ?
Le dernier objectif de prix pour Regeneron Pharmaceuticals (NASDAQ:REGN) a été rapporté par Canaccord Genuity le octobre 23, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $850.00 s'attendant à ce que REGN se rise dans les 12 prochains mois (un possible changement de 47.06% upside). 64 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Regeneron Pharmaceuticals (REGN) ?
La dernière note d'analyste pour Regeneron Pharmaceuticals (NASDAQ:REGN) a été fournie par Canaccord Genuity, et Regeneron Pharmaceuticals maintenu leur note buy.
Quand a eu lieu la dernière mise à niveau pour Regeneron Pharmaceuticals (REGN) ?
La dernière amélioration pour Regeneron Pharmaceuticals Inc a eu lieu le mai 14, 2025 lorsque Citigroup a augmenté leur objectif de prix à $700. Citigroup avait précédemment a neutral pour Regeneron Pharmaceuticals Inc.
Quand a eu lieu la dernière dégradation pour Regeneron Pharmaceuticals (REGN) ?
La dernière réduction pour Regeneron Pharmaceuticals Inc a eu lieu le mai 30, 2025 lorsque Wells Fargo a changé leur objectif de prix de $700 à $580 pour Regeneron Pharmaceuticals Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Regeneron Pharmaceuticals (REGN) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Regeneron Pharmaceuticals, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Regeneron Pharmaceuticals a été déposée le octobre 23, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 23, 2026.
La note d'analyste pour Regeneron Pharmaceuticals (REGN) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Regeneron Pharmaceuticals (REGN) était un maintenu avec un objectif de prix de $850.00 à $850.00. Le prix actuel de Regeneron Pharmaceuticals (REGN) est de $578.00, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.